 TAMPA, Fla., Oct. 04, 2021 GLOBE NEWSWIRE -- Pacira BioSciences, Inc. Nasdaq: PCRX, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has received a Paragraph IV Certification Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc. of Princeton, New Jersey, submitted an Abbreviated New Drug Application ANDA to the U.S. Food and Drug Administration FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL bupivacaine liposome injectable suspension in the United States. 